Genmab A/S (NASDAQ:GMAB) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $50.00 target price on the stock.

GMAB has been the subject of several other research reports. Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $21.29 on Thursday. The stock has a fifty day simple moving average of $21.07 and a two-hundred day simple moving average of $23.98. The firm has a market capitalization of $14.09 billion, a PE ratio of 20.67, a PEG ratio of 0.59 and a beta of 0.97. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter in the prior year, the business posted $0.47 EPS. On average, sell-side analysts forecast that Genmab A/S will post 1.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares in the last quarter. Blue Trust Inc. grew its holdings in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares in the last quarter. R Squared Ltd purchased a new position in Genmab A/S during the 4th quarter valued at about $93,000. Allspring Global Investments Holdings LLC increased its position in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares during the period. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.